Shanghai Pharmaceuticals subsidiary receives drug registration certificate for Paclitaxel Injection
According to 36Kr, Shanghai Pharmaceuticals announced that its subsidiary Shanghai Jinhe Biopharmaceutical Co., Ltd. has received the National Medical Products Administration drug registration certificate for Paclitaxel Injection, approved for production. The drug is for advanced ovarian cancer, breast cancer, and non-small cell lung cancer, and its production approval may help expand market share but carries the risk of sales not meeting expectations.
Key facts
- 01Shanghai Jinhe Biopharmaceutical Co., Ltd. received the NMPA drug registration certificate for Paclitaxel Injection.
- 02The drug is approved for production and is used to treat advanced ovarian cancer, breast cancer, and non-small cell lung cancer.
- 03Approval is expected to help Shanghai Pharmaceuticals expand its market share.
- 04There is a risk that sales may not meet expectations.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.
- 上海医药：紫杉醇注射液获国家药监局批准生产 · 36氪